Distributor inventory | Tablet

Type 2 diabetes mellitus; to improve glycaemic control along with diet and exercise when dual therapy is appropriate

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin release and reducing glucagon. Metformin decreases hepatic glucose production and improves insulin sensitivity, lowering blood glucose without causing significant hypoglycaemia when used alone.

Oral tablet. Take as prescribed, usually with meals to reduce stomach upset. Swallow whole with water; do not crush/chew. Maintain diet/exercise plan and monitor blood glucose regularly.

Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, headache, dizziness, upper respiratory tract infection, hypoglycaemia (especially with other antidiabetics), metallic taste

Prescription-only antidiabetic. Metformin may rarely cause lactic acidosis—risk increases with severe kidney disease, dehydration, sepsis, heavy alcohol use, or hypoxia; assess renal function before and during therapy. Avoid/withhold temporarily during severe illness, dehydration, before major surgery, and around iodinated contrast procedures as advised by doctor. Use caution in liver disease; vildagliptin may affect liver enzymes—periodic LFT monitoring may be recommended. Not for type 1 diabetes or diabetic ketoacidosis.

Alcohol, iodinated contrast media, insulin/sulfonylureas (increased hypoglycaemia risk), corticosteroids and thiazide/loop diuretics (may raise glucose), ACE inhibitors (may increase hypoglycaemia risk), cationic drugs eliminated by renal tubular secretion e.g. cimetidine (may increase metformin levels)

Store below 25°C in a cool, dry place. Protect from moisture and light. Keep in original blister pack and out of reach of children.

Galvus Met 50/500 Tablet, Jalra-M 50/500 Tablet, Zomelis Met 50/500 Tablet, Vildamet 50/500 Tablet, Vildapin-M 50/500 Tablet